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Nurr1, an orphan nuclear receptor, plays an essential
role in the generation and maintenance of dopami-
nergic neurons in the brain. Rare mutations in Nurr1
are associated with familial Parkinson’s disease,
but the underlying basis for this relationship has
not been established. Here, we demonstrate that
Nurr1 unexpectedly functions to inhibit expression
of pro-inflammatory neurotoxic mediators in both
microglia and astrocytes. Reduced Nurr1 expression
results in exaggerated inflammatory responses in
microglia that are further amplified by astrocytes,
leading to the production of factors that cause death
of tyrosine hydroxylase-expressing neurons. Nurr1
exerts anti-inflammatory effects by docking to
NF-kB-p65 on target inflammatory gene promoters
in a signal-dependent manner. Subsequently, Nurr1
recruits the CoREST corepressor complex, resulting
in clearance of NF-kB-p65 and transcriptional
repression. These studies suggest that Nurr1
protects against loss of dopaminergic neurons in
Parkinson’s disease in part by limiting the production
of neurotoxic mediators by microglia and astrocytes.
INTRODUCTION
Parkinson’s disease (PD) is the most prevalent movement
disorder among people over 65 years old. Denervation of dopa-
minergic neurons in the substantia nigra (SN) results in severely
debilitating motor symptoms such as bradykinesia, resting
tremor and rigidity (Farrer, 2006; Fearnley and Lees, 1991).
Although the etiologies of most common forms of PD remain
poorly understood, the disease is generally associated with aninflammatory component that is manifested in part by the pres-
ence of activated microglia (central nervous system-resident
macrophages) and elevated serum or cerebrospinal fluid levels
of pro-inflammatory factors (Block et al., 2007; McGeer and
McGeer, 2008; Nagatsu and Sawada, 2005). Several lines of
evidence suggest that inflammatory mediators such as tumor
necrosis factor (TNF)a, nitric oxide (NO) and Interleukin (IL)-1b
derived from nonneuronal cells, including microglia, modulate
the progression of PD (Brown, 2007; Hartmann et al., 2003; Teis-
mann and Schulz, 2004; Whitton, 2007). Whether inflammation
is an initiating factor of PD in humans is unclear, but intracranial
infusion of bacterial lipopolysaccharide (LPS), a ligand for Toll-
like receptor (TLR)4 and a potent activator of microglia, is suffi-
cient to induce the loss of TH+ neurons in rodents (Meredith
et al., 2008). LPS-induced inflammation can also synergize
with a-Synuclein and Parkin mutations associated with familial
PD to potentiate the loss of tyrosine hydroxylase (TH)+ neurons
in animal models (Frank-Cannon et al., 2008; Gao et al., 2008).
These observations are consistent with the possibility that envi-
ronmental factors, such as infection, may interact with common
but less penetrant susceptibility genes to influence the onset
of most commonly observed sporadic PD cases (Tansey et al.,
2007).
TLRs induce inflammatory gene expression by regulating the
activities and expression of signal-dependent transcription
factors that include members of the NF-kB, AP-1 and IRF fami-
lies (Kawai and Akira, 2007). The TLRs play essential roles in
innate immune responses to microbial pathogens based on their
ability to recognize pathogen-associated molecular patterns
(Akira et al., 2006; Medzhitov, 2007). More recently, genetic
loss-of-function experiments in mice have shown that TLRs
contribute to the pathogenesis of a number of diseases in which
inflammation is known to play a pathogenic role, including
atherosclerosis, inflammatory bowel disease, and liver fibrosis
(Atkinson, 2008). These results are consistent with TLRs being
able to signal in response to the generation of endogenously
derived ligands, such as components of necrotic cells.Cell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc. 47
Nurr1 (NR4A2) belongs to the nuclear receptor (NR)4 family of
orphan nuclear receptors and is known to function as a constitu-
tively active transcription factor by binding to target genes as
a monomer, homodimer or heterodimer with retinoid X receptors
(RXRs) (Aarnisalo et al., 2002; Maira et al., 1999; Wang et al.,
2003). Deletion of the Nurr1 gene in mice results in a severe
reduction in dopaminergic neurons and perinatal lethality
(Zetterstrom et al., 1997), consistent with an essential role for
Nurr1 in the development and/or maintenance of dopaminergic
neurons. Human mutations resulting in reduced expression of
Nurr1 are associated with late-onset familial PD (Le et al.,
2003), indicating that Nurr1 may play a protective role.
Nurr1 is also expressed in nonneuronal cell types and Nurr1
mRNA is induced by inflammatory stimuli, including LPS, in
macrophages (Barish et al., 2005; Pei et al., 2005). Intriguingly,
recent observations suggest that members of the NR4
family can function as both activators and repressors of cell
type-specific inflammatory responses. For instance, Nurr1
suppresses expression of inflammatory response genes in
human macrophages that are implicated in the development of
arthrosclerosis (Bonta et al., 2006). In contrast, Nurr1 promotes
the development of mouse and human Th17 T cells that
contribute to the pathogenesis of multiple sclerosis (Doi et al.,
2008). However, the molecular mechanisms by which Nurr1
controls transcriptional activation or repression of inflammatory
responses have not been established, and the potential impact
of Nurr1 function on the inflammatory component of PD has
not been evaluated.
Here, we present evidence that Nurr1 plays an essential role
in both microglia and astrocytes as a signal-dependent tran-
scriptional repressor of genes that encode pro-inflammatory
neurotoxic factors. Nurr1 functions as a key component of
a negative feedback loop in both microglia and astrocytes by
recruiting CoREST corepressor complexes to NF-kB target
genes. CoREST complexes, in turn, mediate the turnover of
NF-kB and restore activated gene expression to a basal state.
Loss of Nurr1 function in extraneuronal cells of the SN results
in exaggerated and prolonged inflammatory responses that
accelerate the loss of dopaminergic neurons in response to
LPS or overexpression of a mutant form of a-Synuclein (A30P)
associated with familial PD (Kruger et al., 1998).
RESULTS
Nurr1 Protects TH+ Neurons from LPS-Induced
Inflammation In Vivo
Studies demonstrating that Nurr1 mRNA is upregulated by LPS
in macrophages (Barish et al., 2005; Pei et al., 2005) raised the
question of whether it might also be expressed in nonneuronal
cells and influence the development of PD. Analysis of Nurr1
protein and mRNA levels in primary human and mouse microglia,
primary human astrocytes, and the BV2 microglia cell line
demonstrated significant protein expression under basal condi-
tions and induction of Nurr1 mRNA in microglia in response to
LPS (see Figures S1A–S1E available with this article online and
data not shown). Similarly, Nurr1 protein colocalized with the mi-
croglia marker F4/80 (Figure S2E) and Nurr1 mRNA was induced
approximately 2-fold in the SN 6 hr following stereotaxic injection48 Cell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc.of LPS (Figure S1F). To investigate the potential role of Nurr1 in
PD pathology, we evaluated the impact of reducing Nurr1
expression. Since Nurr1-deficient mice die shortly after birth,
we performed stereotaxic injections of lentiviruses encoding
two independent shRNAs against Nurr1 (shNurr1-1 and
shNurr1-2) or control shRNA (shCtrl) into the SN of adult wild-
type mice (Figure S2A). shNurr1-1 and 2 efficiently and specif-
ically reduced Nurr1 mRNA and protein expression in the SN, as
determined by qPCR and immunostaining (Figures S2B–S2E).
A comparison of lentivirus-directed GFP expression with cell-
specific markers indicated preferential transduction of non-
neuronal cells, including microglia and astrocytes (Figure S2G).
The lentiviral injection was followed two days later by injection
of LPS into the same coordinates. We then analyzed the magni-
tude of the inflammatory response by qPCR 6 hr after LPS
injection and quantified TH+ neurons by immunohistochemistry
(IHC) 7 days after LPS injection.
Loss of TH+ neurons following LPS injection normally takes
2–3 weeks (Meredith et al., 2008). However, stereological anal-
ysis revealed a significant decrease in TH+ neurons in the SN
of shNurr1 lentivirus-injected mice compared to shCtrl-injected
animals after only 7 days of LPS treatment (Figures 1A and
1B). Interestingly, a pathological morphology of TH+ neurons
with reduced or absent processes and alterations in the size
and shape of the cells was observed more often in the shNurr1
groups (Figures S2E and 1B). In addition, pathological TH+ cells
were observed close to activated microglia (Figure S2F). The
accelerated loss of TH+ neurons following Nurr1 knockdown
required LPS injection, as it was not observed in buffer (PBS)-
injected animals (Figure 1C and D). In addition, LPS injection
was associated with detection of caspase-3 cleavage, suggest-
ing that loss of TH+ cells was due to cell death rather than to loss
of TH expression (Figure S2G) (Sakurada et al., 1999). Reduction
of Nurr1 expression in the SN also resulted in exaggerated
expression of inflammatory mediators in response to LPS injec-
tion, including iNOS, TNFa and IL1b (Figures 1E–1G).
We also examined whether Nurr1 exerted neuro-protective
effects in the context of overexpression of an aSynuclein
mutant (A30P) associated with familial PD by combining stereo-
taxic injection of shNurr1- or shCtrl-lentivirus with a lentivirus
encoding mutant aSynuclein (A30P). A30P expression alone
caused weak inflammation in the SN, whereas reduction of
Nurr1 expression in the context of A30P expression resulted in
a dramatic increase in expression of numerous inflammatory
response genes, including TNFa and IL1b, and significant loss
of TH+ neurons (Figures S3A–S3C and data not shown). In
concert, these experiments indicate that Nurr1 limits inflamma-
tory responses in the CNS and protects TH+ neurons from
LPS- and a-Synuclein (A30P)-induced toxicity.
Glia-Mediated Inflammation Contributes to the Death
of TH+ Neurons
To define the cell types responsible for LPS-mediated inflamma-
tion in the SN, we evaluated the responses of human and mouse
microglia, astrocytes and neurons to LPS. These experiments
demonstrated that microglia are orders of magnitude more
responsive than astrocytes or neurons, exemplified by the
pattern of TNFa induction in primary mouse and human
microglia and astrocytes and the neuronal Neuro2A (mouse
neuroblastoma) cell line (Figures 2A and S4F). These results
are consistent with the expression patterns of TLR4, corecep-
tors and down-stream signaling molecules in neurons and glial
cells (Figures S4A–S4E). Although, TLR4 expression was virtu-
ally absent from the neuronal cell lines examined, we tested
whether LPS could directly induce the death of these cells.
Three different neuronal cell lines, Neuro2A, SK-N-SH and
PC12, were incubated with LPS for 24h. No significant cell death
was observed by TUNEL assay or caspase-3 cleavage, in
contrast to the effects of TNFa plus cyclohexamide (CHX) treat-
ment (Figures 2B and S4G). In addition, knockdown of Nurr1 in
Neuro2A cells did not increase the sensitivity to LPS or death
signaling (TNFa plus CHX) as determined by TUNEL assay
(Figure 2C).
Figure 1. Nurr1 Suppresses LPS-Induced
Inflammation and Loss of TH+ Neurons
(A) TH-DAB staining of a representative brain
section of mice injected with shCtrl- or shNurr1-
lentivirus and LPS is shown at AP 3.3 mm.
Regions indicated by a rectangle in the injected
side of the brain are enlarged in the right panels.
Scale bars: 200 mm, right panels and 50 mm, left
panels.
(B) Quantification of TH+ cell numbers in the
shNurr1 groups compared to the shCtrl-injected
and the uninjected side. Bars indicate normal
(black) and pathological (gray) TH+ neurons. See
Supplemental Experimental Procedures for the
definition of normal/pathological TH+ neurons.
Asterisk, p < 0.01 compared to the numbers from
shCtrl-lentivirus-injected. (n = 5).
(C) Fluorescence-TH staining of a representative
brain section of mice injected with shCtrl- or
shNurr1-lentivirus followed by PBS or LPS. Exper-
imental diagram is indicated at the top. The scale
bar represents 200 mm.
(D) Quantification of TH+ cell numbers in the setting
of Nurr1 knockdown followed by LPS or PBS
injection. Asterisk, p < 0.002 compared to PBS
injection (n = 4).
(E–G) Expression of iNOS (E), TNFa (F) and IL1b (G)
mRNA in Nurr1-knockdown SN 6 hr after LPS
injection as determined by qPCR and normalized
to HPRT expression (n = 4). Error bars represent
SD. Asterisk, p < 0.01 compared to shCtrl/PBS-
injected; **, p < 0.01 compared to shCtrl/LPS-
injected samples.
Error bars represent the SD.
Based on these results, we evaluated
the consequences of reducing Nurr1
expression in microglia on LPS responses.
Knockdown of Nurr1 expression in BV2 mi-
croglia using specific lentivirus-encoded
shRNAs led to significant increases in
LPS-dependent expression of inflamma-
tory mediators, including TNFa, iNOS and
IL-1b (Figures 2D–2F). Similar results
were observed in the primary mouse
(Figure S5 and S6A-C) and human (data not shown) microglia.
To explore whether loss of Nurr1 in microglia resulted in secretion
of mediators exhibiting preferential toxicity for TH+ neurons, we
knocked down Nurr1 expression using lentivirus-encoded
shRNAs in BV2 cells and tested the activity of conditioned media
(CM) after LPS stimulation on in vitro differentiated neurons and
glial cells derived from mouse neuronal stem cells (NSC). CM
from shNurr1-BV2 cells resulted in the death of nearly all TH+
neurons, with a significantly smaller effect on gamma-aminobuty-
ric acid (GABA)-positive neurons and no significant effect on
glial fibrillary acidic protein (GFAP)-positive astroglial cells
(Figure 2G-I).
Experiments using neuron and glia coculture in vitro suggest
that activation of innate immunity in the CNS can trigger
neuronal death (Lehnardt et al., 2003). Since NSC-derivedCell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc. 49
Figure 2. Microglia Initiate LPS-Mediated
Inflammation and Astrocytes Propagate
the Production of Neurotoxic Factors
(A) Expression of TNFa mRNA upon LPS stimula-
tion in primary microglia, astrocytes and Neuro2A
cells.
(B) Effect of LPS or TNFa + cycloheximide (CHX) on
viability of the indicated neuronal cell lines deter-
mined using a TUNEL ELISA assay. *, p < 0.01
compared to untreated sample (no Tx) (white).
(C) Effect of Nurr1 knockdown in Neuro2A cells on
sensitivity to TNFa + CHX assessed by TUNEL
ELISA assay.
(D–F) Effect of Nurr1 knockdown inBV2 cells on
LPS-induced expression of TNFa (D), iNOS (E)
and IL1b (F) mRNA. *, p < 0.01 compared to no
stimulation (Ctrl); **, p < 0.01 compared to LPS
stimulation of shCtrl-BV2 cells.
(G) Scheme of conditioned media (CM) and cell
death assay. CMs were harvested from shCtrl-
and shNurr1-BV2 cells that were stimulated with
LPS for 24h. Neurons or glial cells were assayed
for specific markers by immunostaining and for
cell death by TUNEL assay.
(H) Effect of CM from LPS-treated shCtrl-BV2 cells
and a mixture of the CMs from shNurr1-1- and
shNurr1-2-infected BV2 cells (shNurr1) on neurons
and glial cells derived from in vitro differentiated
neural stem cells (NSC). TUNEL assay was
performed on TH-, GABA- or GFAP-positive cells
derived from mouse NSC. Numbers of TUNEL-
negative live cells are shown. TH-positive cells
are indicated in red.
(I) The percentages of TUNEL-positive population
are shown. *, p < 0.01 and **, p < 0.001 compared
to no treatment (no TX).
(J) Effect of Nurr1 knockdown in microglia and
astrocytes on the production of neurotoxic factors.
Primary mouse microglia and astrocytes were
infected with shCtrl- or shNurr1-lentivirus. Cells
were treated with LPS for 2h and washed exten-
sively with PBS. Cells were cultured for another
24h to generate CM. For sequential CM assay,
CMs harvested from microglia were cultured with
lentivirus-infected astrocytes for 24 hr. Then,
CMs were harvested and tested for effect on
viability of Neuro2A cells.
Error bars represent the SD.neurons always coexist with astrocytes, it is possible that astro-
cytes contributed to the neurotoxic effect of the microglia CM.
To explore this possibility, we performed sequential CM exper-
iments employing isolated primary microglia and astrocytes and
using Neuro2A cells as a read-out for neurotoxicity. Primary
murine astrocytes and microglia were infected with shCtrl- or
shNurr1-lentivirus used for the injection into the SN. Cells
were then stimulated with LPS and CM was harvested as
described in Figure 2G. CM of microglia infected with shNurr1
induced significant cell death in Neuro2A cultures, whereas
CM of astrocytes infected with shNurr1 had much less effect
on the death of Neuro2A cells. Intriguingly, sequential condi-50 Cell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc.tioning of media from microglia to astrocytes indicated that
astrocytes significantly amplified the production of neurotoxic
factors when exposed to microglia-conditioned media
(Figure 2J lane 2 to lane 6 and 7). This effect was further
increased when expression of Nurr1 was reduced in astrocytes
(Figure 2J lane 3 to lane 8 and 9). We conclude that microglia
are the initial responders to LPS-mediated inflammation and
that astrocytes amplify the production of neurotoxic factors
after the microglial activation. The knockdown of Nurr1 in either
microglia or astrocytes increases the toxicity of CM, suggesting
that Nurr1 inhibits the production of neurotoxic factors in both
cell types.
Figure 3. Nurr1 Acts as an RXR-Indepen-
dent, GSK3b-Dependent Transrepressor
for NF-kB
(A) ChIP assay of Nurr1 on the TNFa-promoter in
response to LPS and effect of the GSK3b-specific
inhibitor SB216763 (SB21). BV2 cells were
preincubated with DMSO or 30 mM SB21 for 1h
followed by LPS stimulation for the indicated times
before ChIP assay. Data are displayed as fold
enrichment over control IgG.
(B) Repression activities of Nurr1 mutants.
RAW264.7 cells were transfected with wild-type
Nurr1, P-box mutant (CEAA) and I-box mutant
(KLL). iNOS-promoter activity in RAW264.7 cells
in response to LPS was measured by luciferase-
reporter assay. *, p < 0.01 compared to control
(Mock).
(C) Effect of knockdown of Ubc9 on Nurr1 repres-
sion of iNOS-promoter activity. *, p < 0.01
compared to Nurr1 with control siRNA.
(D) Identification of the predominant SUMOylation
sites of Nurr1. Flag-tag mutants of Nurr1 were
transfected into HeLa cells. SUMOylation assay
was performed as described in Supplemental
Experimental Procedure.
(E) Effect of reconstitution of Nurr1 shRNA-2 BV2
cells with nontargeted (NT) WT and mutant forms
of Nurr1 that are not recognized by shNurr1-2.
Endogenous iNOS mRNA levels are shown relative
to levels in untreated BV2 cells transduced with
control shRNA and mock Nurr1 lentivirus. *, p <
0.01 compared to mock control cells.
(F) Effect of LPS stimulation on interaction of Nurr1
and p65 in BV2 cells. Lysates of BV2 cells
stimulated with LPS for the indicated times were
immunoprecipitated with anti-Nurr1 antibody and
western blots were developed with anti-p65
antibody.
(G) Effect of SB21 on Nurr1/p65 interaction. BV2
cells were incubated with SB21 at the indicated
concentrations for 1h prior to stimulation with
LPS. IP and western blotting were performed as
described in (F).
(H) Effect of siRNA against GSK3b on Nurr1-
mediated repression of iNOS-promoter activity.
Nurr1 expression vector was transfected into
RAW264.7 cells together with control siRNA or
siRNA against GSK3b. *, p < 0.01 compared to
Nurr1 with control siRNA.
(I) Effect of S468A mutation of p65 on Nurr1-
mediated repression of iNOS-promoter activity.
Error bars represent the SD.Nurr1-Mediated Transrepression Requires GSK3b-
Dependent Recruitment of Nurr1 Monomers to p65
Chromatin immunoprecipitation (ChIP) experiments indicated
that Nurr1 was recruited to LPS-responsive promoters following
LPS treatment, exemplified by the TNFa promoter (Figure 3A),
suggesting that it was acting locally to repress transcription.
Two different general mechanisms of NR-mediated repression
have been described: active repression, involving sequence-
specific DNA binding, and transrepression, involving tethering
of NRs to negatively regulated target genes via protein-protein
interactions (Glass and Ogawa, 2006). A mutant of Nurr1
(Nurr1C280A/E281A, CEAA), defective for sequence-specific DNAbinding and unable to activate NGFI-B responsive element
(NBRE)-luciferase, a reporter for Nurr1 monomer-binding, was
fully able to repress iNOS induction by LPS (Figures 3B and S6D).
In addition, mutations directed at the heterodimerization (I-box)
domain (Aarnisalo et al., 2002) of Nurr1 (Nurr1K555A/L556A/L557A,
KLL) that prevented its ability to activate a Nurr1/RXR-depen-
dent (DR5)-promoter did not interfere with Nurr1-mediated
repression of iNOS (Figure 3B). On the other hand, this I-box
mutation increased transcriptional activation of Nurr1 monomers
through the NBRE element, as previously reported (Aarnisalo
et al., 2002) (Figure S6D). We conclude that Nurr1 inhibits LPS
responses by a transrepression mechanism.Cell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc. 51
SUMOylation of NRs has recently been established to play
important roles in transrepression (Pascual et al., 2005). Since
it is known that Nurr1 interacts with the protein inhibitor of
activated STAT (PIAS) 4 (Galleguillos et al., 2004), which is
a SUMO E3 ligase, we examined whether SUMOylation is also
involved in Nurr1-mediated repression. As shown in Figure 3C,
knockdown of Ubc9, an essential E2 enzyme for SUMOylation
(Hay, 2005), reversed Nurr1-mediated repression of iNOS,
suggesting that SUMOylation is required. Next, we confirmed
that Nurr1 could be SUMOylated with SUMO2 and SUMO3 using
PIAS4 as an E3 ligase (Figure S6E and F) and found that IL1b
stimulation could induce SUMOylation of Nurr1 in the absence
of overexpression of PIAS4 (Figure S6F). Mutational studies
demonstrated that lysine 558 and, to a lesser extent lysine
576, are essential SUMO sites of Nurr1 (Figure 3D). Since both
K558R and K576R mutants are located in the ligand binding
domain and close to the I-box and RXR is not required for repres-
sion activity (Figure 3B and Figure S6D), we hypothesize that
SUMOylation is required for monomerization of Nurr1. Consis-
tent with this, K558R and K576R mutants were less able to
activate the NBRE reporter and preferentially activated the
DR5 reporter (Figure S6G). In addition, reconstitution of BV2
microglia cells expressing the Nurr1 shRNA-2 with a nontargeted
(NT) form of WT Nurr1 reversed hyperactivation of the endoge-
nous iNOS and TNFa genes, while the nontargeted forms of
the SUMOylation mutants (Nurr1 K558R and K576R) did not
(Figures 3E and S6H and S6I).
Since transrepression requires the tethering of NRs to other
transcription factors, we tested whether Nurr1 could bind to
transcription factors involved in inflammation, such as NF-kB.
Coimmunoprecipitation (co-IP) assays of Nurr1 in BV2 cells
showed interaction with NF-kB-p65 that was significantly
enhanced by LPS treatment and independent of changes in
Nurr1 protein levels (Figures 3F and S6A). Phosphorylation of
Serine-468 (S468) in p65 is associated with negative regulation
of NF-kB signaling (Buss et al., 2004) and can be mediated by
GSK3b, which is activated following TLR4 stimulation in human
monocytes (Martin et al., 2005). Furthermore, inactivation of
GSK3b results in increased NF-kB-dependent transcription of
TNFa without changing the kinase activity of the IKK complex
or the nuclear translocation of p65 (Buss et al., 2004). Therefore,
we hypothesized that S468 phosphorylation of p65 by GSK3b
might provide the docking site for tethering of Nurr1. Consistent
with this possibility, the GSK3b-specific inhibitor SB216763
(SB21) inhibited the interaction of Nurr1 and p65 in BV2 cells in
a dose-dependent manner (Figure 3G and Figure S7D) and
prevented the recruitment of Nurr1 to the TNFa-promoter, as
determined by ChIP assay (Figure 3A). To further confirm
GSK3b involvement, we performed TNFa-luciferase reporter
assays in RAW264.7 cells cotransfected with a kinase-dead
mutant of GSK3b (GSK3b-K85R mutant, GSK3b-KD). GSK3b-
KD expression abolished the Nurr1-mediated transrepression
of the TNFa-promoter in a dose-dependent manner (Figure S7B).
Furthermore, knockdown of GSK3b completely prevented
Nurr1-mediated iNOS repression (Figure 3H). We further vali-
dated the contribution of phospho-S468 in p65 by exchanging
S468 for alanine (S468A). The p65 S468A mutant, but not wild-
type p65, reversed Nurr1-mediated iNOS repression in52 Cell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc.RAW264.7 cells in a dose-dependent manner (Figure 3I and
Figure S7E). Finally, GSK3b stimulated the in vitro interaction
of Nurr1 with wild-type p65 but not with p65-S486A (Figure S7C).
The CoREST-Repressor Complex Is Required
for Nurr1-Mediated Transcriptional Repression
Transcriptional repression requires the recruitment of multipro-
tein complexes assembled on central scaffolding proteins
referred to as corepressors. We used siRNAs against various
candidate corepressors in the iNOS-luciferase reporter assay
and identified CoREST as being essential for Nurr1-mediated
repression (Figure 4A and Figure S8A). CoREST has been
considered to be dedicated to repression of neuronal genes in
nonneuronal cells or early precursors by binding to neuron-
restrictive silencer factor (NRSF)/RE1-silencing transcription
factor (REST) (Ballas et al., 2005). CoREST assembles many
chromatin-modifying enzymes, including histone methyltrans-
ferase G9a, histone demethylase, lysine-specific demethylase
(LSD1) and histone deacetylase (HDAC) 1 and 2 (Shi et al.,
2003). Using Nurr1-mediated repression of iNOS-luciferase as
an assay, we observed that G9a, LSD1 and HDAC1 were also
required for Nurr1-CoREST-mediated repression (Figure S8B).
Using co-IP, we also found that LPS stimulated interaction of
Nurr1 and CoREST in BV2 cells (Figure 4B and Figure S8C).
Although the CoREST complex consists of many proteins, the
interaction between Nurr1 and CoREST seemed to be direct,
as indicated by in vitro GST-pull down assay (Figure S8D). This
interaction was mediated by the DNA-binding domain of Nurr1
(Nurr1-DBD) (Figure S8E). When Nurr1-DBD was overexpressed
in HeLa cells, the interaction between Nurr1 and CoREST was
inhibited in a dose-dependent manner (Figure S8F). Further-
more, overexpression of the Nurr1-DBD in RAW264.7 cells
altered Nurr1-mediated repression of iNOS-promoter activity
(Figure S8G).
Since Nurr1 can be phosphorylated by serine/threonine
kinases (Nordzell et al., 2004), we speculated that signal-depen-
dent phosphorylation might contribute to the Nurr1-CoREST
interaction. Nemo-like kinase (NLK) received our attention
because NLK is known to be involved in the repression of various
transcription factors (Yasuda et al., 2004). NLK cooperates with
TGFb-activating kinase 1 (TAK1) and homeodomain-interacting
kinase 2 (HIPK2) in Wnt signaling (Kanei-Ishii et al., 2004). Knock-
down of NLK abolished Nurr1 repression of iNOS-promoter
activity, whereas HIPK2 knockdown was much less effective
and TAK1 had no effect (Figure 4C and Figure S9A). Furthermore,
overexpression of kinase-dead NLK (NLKK155M, NLK-KD) in
RAW264.7 cells inhibited Nurr1-mediated repression of iNOS
in a dose-dependent manner (Figure S9B). Kinase assays
showed that Nurr1, but not CoREST, could be phosphorylated
by active NLK in vitro (Figure 4D). Finally, Nurr1-CoREST interac-
tion was significantly reduced by NLK-knockdown in BV2 cells
(Figure 4E).
To confirm whether CoREST was indeed localized to NF-kB
target gene promoters in association with p65 and Nurr1, we
performed ChIP assays of the iNOS- and TNFa-promoters in
BV2 cells. The occupancy of NF-kB-p65, Nurr1 and CoREST
on both the TNFa- and iNOS-promoters by all three proteins
was strongly increased upon LPS stimulation (Figure 4F,
Figure S9C). On the iNOS-promoter, which exhibits relatively
slower activation kinetics, p65 binding preceded the binding
of Nurr1, which in turn preceded recruitment of CoREST
(Figure 4F). To verify whether this system is indeed functional
in vivo, we performed ChIP assays from microdissected SN after
the stereotaxic injection of LPS into the SN. Consistent with
in vitro data, Nurr1 is recruited to the iNOS- and TNFapro-
moters after LPS stimulation (Figure 4G, Figure S9D). Finally,
we asked whether Nurr1 was indeed essential for the recruitment
of the CoREST complex to target gene promoters. ChIP experi-
ments were performed using shNurr1- or shCtrl-BV2 cells. In the
absence of Nurr1, CoREST was not recruited to the TNFa-
promoter (Figure 4H, left panel). Interestingly, under these condi-
tions, p65 was present at the TNFa-promoter for extended times
(Figure 4H, right panel). Regulation of p65 acetylation by HDACs,
including HDAC1, is known to determine the duration of tran-
Figure 4. CoREST Repressor Complex Is Required for
Nurr1-Mediated Repression
(A) Corepressor requirements in Nurr1-mediated repression. iNOS-
luciferase and Nurr1-expression or control vector as well as siRNAs
against the indicated corepressors were transfected into RAW264.7
cells and iNOS-promoter activity was assayed. *, p < 0.01 compared
to Nurr1 with control siRNA.
(B) Interaction of Nurr1 and CoREST in BV2 cells. Co-IP was performed
with anti-CoREST antibody and western blots were developed with
anti-Nurr1 antibody.
(C) Effect of siRNAs against the indicated targets on Nurr1-mediated
repression of iNOS-promoter activity. *, p < 0.01, **, p < 0.001
compared to Nurr1 with control siRNA.
(D) NLK in vitro kinase assay using GST-Nurr1 and GST-CoREST
as substrates. Arrows indicate phosphorylated GST-Nurr1 and auto-
phosphorylation of NLK. The migration position of GST-CoREST is
indicated by an asterisk. GST substrates and methods are provided
in Supplemental Experimental Procedures and Figure S7D.
(E) Effect of NLK knockdown on interaction of Nurr1 and CoREST. BV2
cells were transfected with siRNA against NLK or control siRNA. Co-IP
of Nurr1 and CoREST was performed as described in (B).
(F) Recruitment of Nurr1, CoREST and p65 to the iNOS promoter in
BV2 cells shown by ChIP assay. Data represent fold enrichment of
iNOS-promoter precipitated by the indicated antibodies compared
to control IgG as determined by qPCR.
(G) ChIP analysis of Nurr1 on the iNOS promoter in the SN before and
after LPS stimulation. Data are shown as averages of fold enrichment
against control IgG and SD.
(H) Effect of Nurr1 knockdown on recruitment of CoREST (left) and p65
(right) to the TNFa promoter in BV2 cells. ChIP data are shown as fold
enrichment over control IgG.
Error bars represent the SD.
scription (Ashburner et al., 2001). HDAC1 is recruited to
TNFa or iNOS-promoter in an LPS-dependent manner;
however, this recruitment is severely impaired in the
absence of Nurr1 (Figure S9E). Finally, to verify an
in vivo role for the genes identified to be involved in
Nurr1/CoREST transrepression pathway, BV2 cells were
transfected with siRNAs targeting their corresponding
mRNAs and were tested for the ability to increase the
production of neurotoxic factors. As shown in
Figure S10A, knockdown of each of the molecules
engaged in this Nurr1/CoREST-mediated transrepression
pathway induced significantly higher death of Neuro2A cells
compared to control siRNA, as detected by TUNEL ELISA assay.
Nurr1 Represses the Production of Neurotoxic Factors
in Astrocytes
The observation that astrocytes could amplify the neurotoxic
effects initiated by microglia (Figure 2J) suggested that pro-
inflammatory cytokines secreted by activated microglia such
as TNFa and IL1b could activate the astrocytes and induce the
transcription of inflammatory neurotoxic mediators (Figures
2D–2F and Figure S6A-B). Consistent with this possibility, the
receptors for TNFa and IL1b are highly expressed in primary
mouse and human astrocytes, but not microglia (Figures 5A–
5B and S11A-S11B). Nurr1 protein was expressed in resting
human and mouse astrocytes (Figure S1E and S1F) and Nurr1
mRNA was induced by IL1b or TNFa (Figure 5C, D andCell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc. 53
Figure S11C,D). To test the possibility that Nurr1 also partici-
pates in a signal-dependent negative feedback mechanism in
astrocytes, primary mouse and human astrocytes were infected
with shCtrl- and shNurr1-lentivirues. Activated astrocytes can
upregulate many pro-inflammatory genes, including the iNOS
and Ncf1 genes upon IL1b and TNFa stimulation, which are
essential enzymes for NO and reactive oxygen species (ROS)
Figure 5. Nurr1 Suppresses Inflammatory Mediators in Murine
Astrocytes
(A and B) Expression of IL1R1 (A) and p55TNFR (B) mRNA in primary
astrocytes and microglia as determined by qPCR assay. *, p < 0.01.
(C) Responses of primary mouse microglia or astrocytes to TNFa or IL1b
for 6h. iNOS mRNA level was determined by qPCR.
(D) Regulation of Nurr1 mRNA in mouse primary astrocytes stimulated
with TNFa or IL1b for the indicated times.
(E–I) Effect of knockdown of Nurr1 in astrocytes on induction of NO (F –
measured by Greiss reaction) and mRNAs encoding neurotoxic mediators
(E, G-I). Mouse primary astrocytes were infected with shCtrl- or shNurr1-
lentivirus and cells were stimulated with TNFa or IL1b for 6 hr.
Error bars represent the SD.54 Cell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc.production, respectively. Knockdown of Nurr1 in astrocytes
drastically increased mRNA expression of both iNOS and Ncf1
in response to IL1b and TNFa and upregulated NO production
(Figures 5E–5G, S11E, andS11F). Furthermore, activated astro-
cytes can produce macrophage colony stimulating factor
(CSF1), which supports the proliferation of microglia (Thery
et al., 1992), and knockdown of Nurr1 significantly upregulated
the transcription of CSF1 gene upon both TNFa and IL1b
stimulation (Figure 5H and S11G). In contrast, transcription of
brain-derived neurotrophic factor (BDNF), a known neurotrophin
for dopaminergic neurons, was not affected by knockdown of
Nurr1 (Figure 5I and S11H). These data indicate that Nurr1 also
acts as a transcriptional repressor for inflammatory neurotoxic
mediators in astrocytes.
The Nurr1/CoREST Transrepression Pathway Functions
in Astrocytes
Finally, we asked whether the mechanism of transcriptional
repression by Nurr1 in astrocytes is similar to that in microglia.
Treatment of primary mouse astrocytes with IL1b induced the
interaction of Nurr1 with p65 (Figure 6A) and induced recruitment
of both Nurr1 and p65 to the iNOS-promoter (Figure 6B). Recruit-
ment of Nurr1 to the iNOS promoter was blocked by inhibition of
GSK3b by SB21 (Figure 6C), consistent with TLR4 and IL1b
receptors sharing the MyD88 signaling pathway (Verstrepen
et al., 2008). Nurr1 also interacted with CoREST in astrocytes
in a manner that was stimulated by IL1b (Figure 6D), and both
molecules were recruited to the iNOS-promoter, as was
observed in microglia (Figure 6E). Knockdown of the compo-
nents of CoREST repressor complex such as LSD1, G9a and
HDAC1 also upregulated iNOS, CSF1 and Ncf1 genes, suggest-
ing that the CoREST-complex is required for Nurr1-mediated
transcriptional repression in astrocytes (Figures 6F–6H). Finally,
knockdown of Nurr1 in astrocytes resulted in prolonged
occupancy of p65 on the iNOS promoter (Figure 6I), similar to
results obtained in microglia (Figure 4H).
DISCUSSION
Nurr1 Exerts Anti-Inflammatory and Neuroprotective
Effects in Glia
Although a number of genes have been identified as causes of
familial PD, the majority of cases are sporadic and of unknown
etiology (Farrer, 2006; Moore et al., 2005). An improved under-
standing of the causes of the more common forms of the disease
will therefore be essential in developing broadly applicable treat-
ment strategies. Here, we demonstrate that in addition to its
essential roles in the development and maintenance of dopami-
nergic neurons, Nurr1 plays a previously unexpected role in
protecting these neurons from inflammation-induced neurotox-
icity. Several lines of evidence suggest that this role is due to
its function as an inhibitor of inflammatory gene expression in
microglia and astrocytes (Figure 7A). First, these studies utilized
a model system in which neurotoxicity was induced by LPS,
which is not effectively sensed by neurons and does not directly
cause neuronal death. Second, reduction of Nurr1 expression
in the SN (primarily in microglia and astrocytes) did not in itself
lead to reduction of TH+ neurons but did result in enhanced
Figure 6. The CoREST Complex Is Required for Nurr1-Mediated Repression in Astrocytes
(A) Effect of IL1b stimulation on association of Nurr1 and p65 in mouse primary astrocytes. Lysates of astrocytes stimulated with IL1b for the indicated times
were immunoprecipitated with anti-Nurr1 antibody and Western blots were developed with anti-p65 antibody.
(B) Recruitment of Nurr1 and p65 to iNOS-promoter in mouse primary astrocyte shown by ChIP assay. Data represent fold enrichment of iNOS-promoter
precipitated with the indicated antibodies compared to control IgG as determined by qPCR.
(C) Effect of GSK3b-specific inhibitor SB21 on recruitment of Nurr1 to iNOS-promoter. Data represent fold enrichment of iNOS-promoter precipitated with
antibody against Nurr1 compared to control IgG as determined by qPCR.
(D) Interaction of Nurr1 and CoREST in mouse primary astrocytes. Co-IP was performed with anti-Nurr1 antibody and Western blots developed with anti-CoREST
or anti-Nurr1 antibodies.
(E) Recruitment of Nurr1 and CoREST to iNOS-promoter in mouse primary astrocytes shown by ChIP assay. Data represent fold enrichment of iNOS-promoter
precipitated with the indicated antibodies compared to control IgG as determined by qPCR.
(F–H) Effect of knockdown of the components of CoREST-repressor complex on mRNAs encoding inflammatory mediators. Mouse primary astrocytes were
infected with lentivirus carrying shRNA against CoREST, LSD1, G9a, HDAC1 or control. Cells were stimulated with IL1b for 6h and mRNA expression of iNOS
(F), CSF1 (G) and Ncf1 (H) was determined by qPCR. (I) Nurr1-dependent clearance of p65 from iNOS promoter. ChIP assay was performed in shNurr1- or
shCtrl-astrocyte and data shown as fold enrichment over control IgG of iNOS promoter precipitated with antibody against p65.
Error bars represent the SD.expression of inflammatory mediators and accelerated loss of
TH+ neurons in response to LPS. Finally, reduction of Nurr1
expression in isolated microglia and astrocytes resulted in their
exaggerated production of neurotoxic factors in response to
inflammatory stimuli.
Experiments employing sequential transfer of cell culture
media from microglia to astrocytes or vice versa indicate that
astrocytes can act as amplifiers of microglia-derived mediators
in the production of neurotoxic factors. Collectively, our data
are consistent with a model in which LPS-induced expression
of factors such as IL1b and TNFa by microglia results in para-
crine activation of astrocytes. This activation in turn is predictedto enhance production of toxic mediators by astrocytes that
include NO and ROS. These factors are suggested to act
additively or synergistically with neurotoxic factors produced
by microglia (Figure 7A). Experiments using mixed neuronal
cultures are of particular interest in this regard because they
suggest that activated microglia and astrocytes produce factors
that exhibit relative specificity for TH+ neurons (Figures 2H
and 2I). Conversely, distinct neuronal cell types might exhibit
different sensitivities to neurotoxic factors based on protective
systems, such as those conferred by genes under the control
of the PGC1a coactivitor (St-Pierre et al., 2006). Defining
the specific identities of the pathologically important factorsCell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc. 55
produced by microglia and astrocytes and their relative ability to
exert toxic effects on different types of neurons will be important
future goals.
There is currently no evidence that LPS or bacterial infection
contribute directly to the pathogenesis of PD in humans.
However, the emerging recognition of the roles of TLRs in
a number of inflammatory diseases raises the possibility that
endogenous TLR ligands are generated during aging that
contribute to disease initiation or progression. For example,
components of dying cells, such as Hsp60, have been shown
to trigger TLR4 activity (Lehnardt et al., 2008). Other factors,
such as ATP, can also induce inflammatory responses through
other signaling pathways (Di Virgilio, 2007). A transient event
leading to neuronal injury could thus lead to activation of micro-
glia, with subsequent amplification of inflammation by astro-
cytes. The present findings suggest that Nurr1 protects the
CNS from amplification of inflammatory signaling by microglia-
astrocyte communication. Strategies to suppress expression
Figure 7. Nurr1 Functions to Inhibit Neuro-
toxic Gene Expression in Microglia and
Astrocytes via a CoREST-Dependent Trans-
repression Pathway
(A) Model for communication among microglia,
astrocyte and neurons.
(B) Model for Nurr1/CoREST-mediated repres-
sion. See main text for details.
of neurotoxins either directly or by inter-
fering with microglia/astrocyte communi-
cation may thus have therapeutic utility.
Furthermore, it may be necessary to
suppress the production of neurotoxic
mediators by microglia and astrocytes in
order to obtain reconstitution of func-
tional neuronal circuits using cell-based
therapies (Brundin et al., 2008).
A Nurr1/CoREST Transrepression
Pathway Mediates Feedback
Regulation of Inflammatory
Responses
Members of the NR4A family have been
reported to both positively and negatively
regulate pro-inflammatory genes (Bonta
et al., 2006; Doi et al., 2008; Pei et al.,
2006). The present studies demonstrate
a potent anti-inflammatory activity of
Nurr1 in microglia and astrocytes. We
propose that this anti-inflammatory
activity is mediated by a Nurr1/CoREST
transrepression pathway that operates
in a feedback manner to restore tran-
scription of NF-kB target genes to a basal
state (Figure 7B). In this pathway, Nurr1 is
recruited to NF-kB on inflammatory gene
promoters dependent on GSK3b-medi-
ated phosphorylation of S468 of p65.
Nurr1 subsequently recruits the CoREST corepressor complex
in an NLK-dependent manner. Since HDAC1-mediated deacety-
lation is known to regulate the duration of p65 transcriptional
activity, and HDAC1 is a component of the CoREST complex,
the Nurr1-CoREST axis might have essential roles in terminating
inflammatory responses by p65 clearance from the target
promoters. These studies thus establish an unexpected biolog-
ical role for the CoREST complex, previously considered to
mainly be involved in the repression of neuronal genes in NSCs
or nonneuronal cells (Ballas et al., 2005). We also find that over-
expression of Nur77 and Nor1 in a macrophage cell line can
suppress iNOS activation in response to LPS (K.S., unpub-
lished), suggesting that the CoREST transrepression pathway
may be widely used by members of the NR4A family.
Of interest, reduction of most of the well-established compo-
nents of the CoREST complex severely compromises the
anti-inflammatory activity of Nurr1. Quantitative defects in the
expression or activities of these proteins could thus predispose56 Cell 137, 47–59, April 3, 2009 ª2009 Elsevier Inc.
certain organ systems to inflammation-sensitive pathologies,
such as PD.
EXPERIMENTAL PROCEDURES
Mice and Isolation of Primary Cells
C57BL/6 mice were purchased from Charles River or Harlan and housed
according to UCSD or Salk Institute protocols, respectively. Mouse primary
microglia cells and astrocytes from the cerebrum of P0 pups. After 10–
14 days of culture, microglia cells were isolated from astrocytes by the
magnetic sorting using anti-mouse CD11b beads (Miltenyi). Purity of each
population was over 98%, as determined by FACS. Murine microglial BV2 cells
(kindly provided by Katerina Akassoglou) and macrophage RAW264.7 cells
were maintained with DMEM supplemented with 10% FBS (low endotoxin,
Hyclone) and penicillin/streptomycin. For other cells, details appear in Supple-
mental Experimental Procedures.
Reagents
All smart-pool siRNAs and GIPZ lentivirus shRNAmir were purchased from
Dharmacon and Open Biosystems, respectively. LPS E. coli 0111:B4 used
at 0.1 mg/ml final, SB216763 as indicated, and Cycloheximide used at 10 mg/
ml final were obtained from Sigma. Human and mouse IL1b used at10 ng/ml
final and TNFa used at 50 ng/ml final were from R&D system.
Stereotaxic Injection of lentivirus and LPS
LPS and/or lentiviruses were delivered to the right SN by stereotaxic injection
at AP 3.3 mm, ML 1.2 mm, DV 4.6 mm from bregma (Franklin and Paxi-
nos, 2008). See Supplemental Experimental procedures for full methods.
Immunohistochemistry (IHC)
Experimental animals were anesthetized and perfused transcardially with
0.9% saline followed by 4% paraformaldehyde. Brain samples were postfixed
with 4% paraformaldehyde overnight and equilibrated in 30% sucrose.
Coronal sections of 40 mm were prepared with a sliding microtome. IHC was
performed using mouse anti-tyrosine hydroxylase (Chemicon). Unbiased
quantification of TH-immunoreactive neurons in the SN was performed
according to the optical fractionator principle (Gundersen et al., 1988). See
Supplemental Experimental procedures for full methods.
Transfection Assays
The RAW264.7 mouse macrophage cell line was transiently transfected with
iNOS- or TNFa-promoters directing luciferase expression (Pascual et al.,
2005) using SuperFect (QIAGEN). Double transfections with plasmid DNA and
siRNAs used Transmessenger reagent (QIAGEN). Flag-tagged full-length (FL)
mouse Nurr1 was cloned into p3XFLAG-CMV-7.1 vector (Sigma). Mutant
constructs of Nurr1 were generated with the Quick-change site-direct
mutagenesis kit (Stratagene). Retrovirus production (Openbiosystems) and
infection into BV2 cells were performed according to the manufacturer’s
protocol. Lentivirus p156RRLsinPPTCMV-GFP-PREU3Nhe and pHAGE vector
packaging was done using Virapower (Invitrogen) or pCMV dR8.29 plus
pMD2G, respectively. GIPZ lentivirus shRNAmir (Openbiosystems) packaging
was performed according to the manufacturer’s protocols. See Supplemental
Experimental procedures for full methods.
Biochemical Assays
Cell death detection kit (Roche) was used for TUNEL assay. SUMOylation
assays were performed as described before (Pascual et al., 2005). For endog-
enous co-IP experiments, anti-Nurr1 (E-20, Santa Cruz), anti-CoREST (E-15,
Santa Cruz and Millipore) and anti-p65 (C-20, Santa Cruz) were used for IP
and Western blotting. For immunoprecipitation of tagged proteins, M2 anti-
Flag-agarose (Sigma) beads were used. NLK (Millipore) in vitro kinase reaction
(Kanei-Ishii et al., 2004) was performed using GST-fusion substrates.
Chromatin Immunoprecipitation Assays
For each experimental condition, 23 107 BV2 cells or 63 106 mouse primary
astrocytes were used. Cells were stimulated with LPS for BV2 cells and IL1b forastrocytes for the indicated time before crosslinking for 10 min with 1% form-
aldehyde. Anti-Nurr1 (E-20, Santa Cruz Biotechnology) anti-p65 (C-20, Santa
Cruz Biotechnology), anti-CoREST (Millipore) or control rabbit IgG (Santa Cruz
Biotechnology) were used for IP. See details in Supplemental Experimental
Procedures.
RNA Isolation and Quantitative PCR
Total RNA was isolated by RNAeasy kit (QIAGEN) from cells or SN samples
microdissected from the brain. One microgram of total RNA was used for
cDNA synthesis using Superscript III (Invitrogen), and quantitative PCR was
performed with SYBR-GreenER (Invitrogen) detected by 7300 Real Time
PCR System (ABI). The sequences of qPCR primers used for mRNA quantifi-
cation in this study were obtained from PrimerBank (Wang and Seed, 2003).
Statistical Analyses
Standard deviation, Chi-square and two-tail Student’s t-test were performed
with the Prism 4 program. p < 0.01 was considered significant. For IHC and
IF analyses, Bonferroni was used for post hoc analysis when a significant
difference was found with ANOVA. Unpaired two-tailed t test was used for
other comparisons, including comparisons between control and injected sides
within one group. All data are presented as mean ± SD.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, twelve
figures, and Supplemental References and can be found with this article online
at http://www.cell.com/supplemental/S0092-8674(09)00086-5.
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